RE:RE:RE:RE:RE:RE:Nice gainsDF agree it's a million dollar question for a few of us. After all these years it's nice to see a 2x or 3x but as we know the upside from here is much larger. Sgtx has now traded up to 1.45B MC and they are only in the clinic for Hemophilia. That puts sernova at just over $7 a share and that's comparing a company that is years behind and treating Hemophilia vs Diabetes. It seems like the word is getting out now and if momentum continues the rerating to peers is potentially 10x from current levels. Witkoskis news could speed up this rerating; it might take a Nasdaq listing it might not but if the technology works as you say with world wide patents Sernova has a clear path to walk or be taken out along the way. I don't want to count my eggs before they hatch. There will be ups and down but I'm optimistic and look forward to the story unfolding.